Radiochromium (chromium-51) evaluation of gastrointestinal blood loss associated with placebo, aspirin, and nabumetone
| Autor: | André Lussier, Etienne LeBel |
|---|---|
| Rok vydání: | 1987 |
| Předmět: |
Adult
Male medicine.medical_specialty Side effect Nabumetone Placebo Gastroenterology Placebos Double-Blind Method Statistical significance Internal medicine medicine Humans Antipyretic Aspirin Gastrointestinal tract Isotopes of chromium business.industry Anti-Inflammatory Agents Non-Steroidal General Medicine Butanones Chromium Radioisotopes Immunology Gastrointestinal Hemorrhage business medicine.drug |
| Zdroj: | The American Journal of Medicine. 83:15-18 |
| ISSN: | 0002-9343 |
| DOI: | 10.1016/0002-9343(87)90587-0 |
| Popis: | Gastrointestinal blood loss is one of the most serious clinical events induced by drugs. To date, almost no nonsteroidal anti-inflammatory drug has been shown to be devoid of that side effect in a strictly controlled study. The objective of this study was to assess quantitatively, by use of radioactive chromium (chromium-51)-labeled red blood cells, gastrointestinal blood loss associated with nabumetone (1,000 mg daily), aspirin (3.6 g daily), and placebo. A total of 37 normal subjects, divided among the three treatment groups and a fourth group that received no treatment, were assessed clinically and quantitatively for gastrointestinal blood loss over a period of 28 days of "active" treatment. The results with chromium-51, analyzed on a logarithmic scale, revealed no statistically significant differences between the nabumetone, placebo, and control groups. Gastrointestinal blood loss in the aspirin group, however, was elevated when compared with all other groups at a high level of statistical significance (p less than 0.001). It is concluded that, under conditions in which aspirin causes substantial gastrointestinal microbleeding, nabumetone is not significantly different from placebo. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|